Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Delayed Quote. Delayed Swiss Exchange - 09/21 11:30:08 am
77.07 CHF   -0.18%
04:36pINCYTE : FDA approves Incyte's eczema cream
RE
04:15pINCYTE : FDA approves Incyte's eczema cream
RE
11:55aGLOBAL MARKETS LIVE : Vivendi, EssilorLuxottica, Compass, StageCoach, Allianz...
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

NOVARTIS AG : Credit Suisse sticks Neutral

07/22/2021 | 06:27am EDT

In a research note published by Jo Walton, Credit Suisse gives a Neutral rating to the stock. The target price continues to be set at CHF 90.


ę MarketScreener with dpa-AFX Analyser 2021
All news about NOVARTIS AG
04:36pINCYTE : FDA approves Incyte's eczema cream
RE
04:15pINCYTE : FDA approves Incyte's eczema cream
RE
11:55aGLOBAL MARKETS LIVE : Vivendi, EssilorLuxottica, Compass, StageCoach, Allianz...
03:40aNOVARTIS : Acquires Arctos Medical to Expand Optogenetics Portfolio
MT
02:48aNOVARTIS : Boosts Optogenetics Portfolio With Arctos Medical Acquisition
MT
02:02aNovartis buys gene therapy firm Arctos Medical in vision loss treatment push
RE
01:42aNOVARTIS : acquires Arctos Medical, expanding optogenetics portfolio to bring gene therapi..
PU
09/20NOVARTIS : announces findings from a real-world study of alpelisib demonstrating clinical ..
AQ
09/20MIRATI THERAPEUTICS : taps industry veteran Meek as CEO
RE
09/20NOVARTIS AG : Downgraded from Neutral to Sell by Deutsche Bank
MD
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Financials (USD)
Sales 2021 51 995 M - -
Net income 2021 10 094 M - -
Net Debt 2021 22 236 M - -
P/E ratio 2021 16,9x
Yield 2021 4,24%
Capitalization 172 B 187 B -
EV / Sales 2021 3,74x
EV / Sales 2022 3,49x
Nbr of Employees 109 000
Free-Float 87,0%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 77,07 $
Average target price 102,88 $
Spread / Average Target 33,5%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans J÷rg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG-7.70%186 162
JOHNSON & JOHNSON4.09%431 227
ROCHE HOLDING AG10.52%321 941
PFIZER, INC.19.23%247 816
NOVO NORDISK A/S48.69%229 255
ELI LILLY AND COMPANY37.20%210 000